Organigram Global Inc.
Organigram Global Inc. is a Canadian cannabis company focused on the production and sale of cannabis and cannabis-derived products for medical and adult-use markets. Its portfolio includes dried flower, pre-rolls, vapes, beverages, gummies, concentrates, and other product formats distributed through retail, wholesale, and online channels. The company markets its products under brands such as SHRED, Edison Cannabis Co., Big Bag O’ Buds, Monjour, Trailblazer, BOXHOT, and DEBUNK, giving it a broad consumer reach across multiple segments of the regulated cannabis industry. Organigram Global also participates in the supply of plant cuttings and dried flowers to other licensed producers, supporting broader industry operations. Headquartered in Toronto, Canada, Organigram Global plays a significant role in Canada’s legal cannabis market through cultivation, manufacturing, and branded product development.
C$1.32
+C$0.00 (+0.00%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-5.90% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 62.2% YoY with margins expanding 16.4pp.
Negative free cash flow of -C$25M. The business is consuming cash, not generating it.
2.1x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$309M
▲ +62.2% YoY
Net Income (TTM)
C$87M
▲ +45.5% YoY
Op. Margin
-2.16%
▲ +16.4pp YoY
ROIC
-3.62%
▲ +3.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-C$30M
▼ -1580.8% YoY
Op. Cash Flow (TTM)
-C$27M
▼ -352.4% YoY
Net Debt
-C$20M
Net Cash Position
Cash & Equiv.
C$29M
3Y CAGR: +48.5%
Continue Research
Is Organigram Global (OGI) overvalued?
At a P/E of 2.1, Organigram Global (OGI)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Organigram Global scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Organigram Global a high-quality business?+
Organigram Global scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -2.2% operating margin and a -3.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Organigram Global a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh OGI's valuation and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Drug Manufacturers - Specialty & Generic
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.